ASCO: Overall Survival Up for African-American Men With mCRPC

THURSDAY, June 7, 2018 -- Overall survival is increased for African-American men with metastatic castration resistant prostate cancer (mCRPC) versus Caucasian men treated with docetaxel/prednisone (DP) or a DP-containing regimen, according to a...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news